Strides strengthens its Africa business with acquisition of multiple generic brands from Sandoz
Strides Pharma Science announced that its step‑down subsidiary, Strides Pharma International AG (SPIAG), has entered into…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Strides Pharma
Strides Pharma to market WHO-prequalified generic DMPA-SC in Africa
The company highlights expanded access to affordable contraceptive options through global collaboration
Sustainable packaging solutions in pharma industry
The session on 'Sustainable packaging solutions in pharma' addressed a challenge that is increasingly critical, how to reduce…
Strides Pharma receives USFDA approval for Celecoxib Capsules in multiple strengths
Approval from USFDA allows Strides Pharma to market Celecoxib Capsules 100 mg, 200 mg, and 400 mg in the United States
Strides Pharma recognised in S&P Global Sustainability Yearbook 2025
Strides ranks among the top 10 percent of global companies for ESG performance across environmental, social, and governance…
Strides Pharma subsidiary receives USFDA approval for 60 mg Fluoxetine tablets
Strides Pharma Global secures approval for Fluoxetine Tablets, completing its portfolio for the US market
Strides Pharma secures shareholder and creditor approval for OneSource Pharma CDMO Initiative
Shareholders and creditors back Strides Pharma's plan to create India’s first specialty pharma CDMO
Strides gains USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg
Strides is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity for Theophylline Extended-Release Tablets, 300…
Strides Alathur receives EIR from USFDA for its Chennai facility
The facility manufactures tablets and capsules and supports several current and future products for the US markets
Glenmark, Strides Pharma and Cipla recall products in US
The recall has taken place due to manufacturing issues